Samik Basu is a highly innovative physician-scientist with extensive experience in translational research and the development of novel immune therapies. As the Chief Scientific Officer at Cabaletta Bio, he focuses on advancing cellular immunotherapy and T cell immunology, particularly in the context of cancer and autoimmune diseases. His academic background includes a Doctor of Medicine from Temple University, where he also earned his Bachelor's in Biology. Over the years, Samik has held various leadership roles in prominent organizations, including Adaptimmune and Merck Research Laboratories, where he led translational efforts in immune-oncology. He has received multiple awards for his contributions to science and education, reflecting his commitment to mentoring the next generation of scientists. Samik is not only recognized for his scientific acumen but also for his ability to bridge the gap between research and clinical application, making him a valuable asset in the biotechnology sector.